Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2022—Creative Diagnostics has released a range of Nipah virus recombinant antigens and monoclonal antibody pairs. The monoclonal antibodies can be used as a pair in sandwich ELISA with the recombinant protein or in capture IgM assays. The products are specific to Nipah virus, with no cross-reaction with dengue, Zika, and chikungunya envelope proteins.
May 2022—Proscia and Hamamatsu Photonics are collaborating to accelerate the adoption of digital pathology. The agreement aims to increase the availability of the companies’ best-of-breed solution, which combines Proscia’s Concentriq platform and Hamamatsu’s NanoZoomer series of whole slide scanners, to laboratories. Users of Hamamatsu’s scanners can integrate their images and all other data into an open ecosystem centered around Concentriq. Under the agreement, customers will receive support with implementation.
May 2022—Source Medical Products announced it is carrying CelLock, a kit that standardizes the preparation of formalin-fixed, paraffin-embedded cell blocks. Included in the kit is a proprietary product called CelLGel, which is used in concert with a proprietary filter to collect and process 99.7 percent of the initial patient specimen into the cell block. The filter is included in the cell block to provide a visual cue, the company says, to make the tasks of embedding and microtomy easier and more exacting. The cellular proteomic and genetic information within the specimen is preserved for immunohistochemical, molecular, and ancillary testing.
June 2022—Accelerate Diagnostics announced the release of new performance data on the Accelerate Arc module and blood culture kit.
June 2022—Verichem Laboratories announced the availability of a multilevel set of liquid-stable, ready-to-use clinical reference materials for the calibration and calibration verification of ammonia assays. The materials are universally compatible and can be used with a range of clinical testing systems, including from Abbott Diagnostics, Beckman Coulter, Roche Diagnostics, and Siemens Healthineers.
June 2022—ZeptoMetrix announced the release of its NATtrol SARS-CoV-2 Omicron External Run Control, for research use only, to evaluate the performance of nucleic acid tests for determining the presence of SARS-CoV-2 omicron variant RNA. The control is formulated with purified, intact organisms and is for use with a real-time PCR thermal cycler. The product is available in six 0.5-mL vials and is refrigerator stable at 2° to 8°C.
June 2022—Siemens Healthineers announced the FDA has granted breakthrough device designation for the Advia Centaur serum neurofilament light chain (sNfL) assay, developed in collaboration with Novartis Pharma. The assay quantitatively measures NfL in human serum and plasma and is intended to be used in conjunction with clinical, imaging, and laboratory findings as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower risk, versus higher risk, of multiple sclerosis disease activity.
June 2022—Bio-Rad Laboratories introduced a range of antibodies specific to cemiplimab (Libtayo) that inhibit the binding of the drug to its target, human programmed death receptor-1. The ready-made antibodies are suitable for developing selective and sensitive assays for the bioanalysis and drug monitoring of cemiplimab.
June 2022—Tribun Health announced its expansion into the pharmaceutical market with the appointment of Loic Dartois as vice president of pharma. Dartois joined Tribun Health in March and is developing commercial offerings for the pharma industry. “Digital pathology data combined with best-in-class AI models has the power to improve treatments’ responses to a better targeted population,” Dartois said in a press release. “Thanks to its growing footprint in health care institutions in Europe and North America, Tribun Health is best positioned to support the pharmaceutical industry in its precision medicine transformation using an industry-leading digital pathology platform and deploying a thought leadership AI team.”
June 2020—Sysmex America has expanded its reagent portfolio by becoming a distributor of more than 450 Exbio single-color antibodies, cell stains, and buffering solutions. The company offers a comprehensive variety of analyte-specific reagent and research use only antibodies for immunophenotyping, cell staining and processing, and vitality assays, as well as for other research applications.
